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Abstract 
Background: The Cytochrome P450 enzymes are commonly known for their major role in metabolism. Besides its 
metabolic role, CYP2E1 gene expression has been associated with the onset of diabetic nephropathy. CYP2E1 protein 
elevation has also been reported to be responsible for the production of reactive oxygen species. The aims of this 
study were (i) to optimize and validate a targeted proteomic approach for quantitating CYP2E1 and validating it as 
a suitable clinical test, (ii) to investigate the concurrency between ESI-LCMS-MS quantitated circulating CYP2E1 and 
gold standard indices in the context of outpatient point-of-care clinical settings involving various groups of diabetic 
patients and (iii) to investigate the concurrency profile of circulating CYP2E1 protein, CYP2E1 gene expression and 
reactive oxygen species (ROS). This is a cross sectional study involving three groups of subjects (n = 166): control, 
pre-diabetes, and diabetes. We optimized a targeted proteomic approach for absolute quantification of CYP2E1. 
“YPEIEEK” and “GTVVVPTLYDNQEFPDPEK” were the representative peptides of CYP2E1 for our analytical method. Deu-
terated forms of “YPEIEEK” and “GTVVVPTLYDNQEFPDPEK” were used as internal standards. Lymphocytes were isolated 
from whole blood, microsomes were prepared, followed by in-solution digestion for production of tryptic peptides. 
Amounts of “YPEIEEK” and “GTVVVPTLYDNQEFPDPEK” from patients’ samples were calculated from a calibration curve.
Results: “YPEIEEK” is a unique and reliable representative peptide for CYP2E1 quantification. “GTVVVPTLYDNQEFPD-
PEK” showed poor reproducibility and sensitivity. Incremental amounts of CYP2E1 protein in the peripheral circula-
tion clearly showed concurrency with CYP2E1 gene expression and ROS levels in our study population. Elevations of 
CYP2E1 were observed even when gold standard clinical indicator for glycemic control (HbA1c) was within normal 
reference limits. Quantitated amounts of CYP2E1 protein in the pre-diabetes and diabetes groups showed significant 
difference relative to control group (p < 0.001). No significant differences were observed between the medians of pre-
diabetes and diabetes groups (p = 0.870).
Conclusions: CYP2E1 protein in peripheral blood can be reliably quantitated by the validated targeted proteomic 
approach method. Quantifiable amounts of CYP2E1 preceded abnormal HbA1C levels which indicates quantitation of 
CYP2E1 could be useful as an additional tool for early indication of diabetic risks and it complications.
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Background
Cytochrome P450 (CYP450) is a superfamily of meta-
bolic enzymes commonly known for their primary role 
in the metabolism of endobiotics and xenobiotics [1]. The 
main normal tissue in which CYP450s are expressed is in 
the hepatocytes [2]. Specific forms of CYP450 are present 
in extra-hepatic tissues such as the intestines, lungs and 
lymphocytes [2]. However, peculiar extra-hepatic expres-
sions of specific individual CYP450 isoforms have been 
associated with various pathological conditions such as 
in organ specific cancers [3, 4] and tumors [5], diabe-
tes [6–8] and chronic kidney diseases [9]. The CYP1B1 
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subtype is tumour specific, while the CYP1A family has 
been identified predominantly in several types of organ 
cancers and CYP3A5 is the predominant subtype iden-
tified in lung tumour as well as in lung cancer cells [2]. 
Recent studies have also showed that CYP2E1 expres-
sion in peripheral lymphocytes [7, 8] is elevated in dia-
betes and kidney disorders [9]. The correlation between 
CYP2E1 level in peripheral blood lymphocytes and early 
pathogenesis of diabetic nephropathy has recently been 
demonstrated [10]. Notably, besides the important role 
that CYP450 superfamily plays in xenobiotics and endo-
biotics metabolism, individual CYP450 isoforms may 
pose as candidate markers of a specific disease or pathol-
ogy [11]. If the proposed candidate markers are measur-
able earlier than conventional clinical indices, the former 
may be useful as early indicators of an onset of particular 
disease. Early indicators of diseases are essential for pre-
vention of further progression and for early planning of 
effective interventions.
Rapid methods to quantitate these diseases’ specific 
CYP450 isoforms will allow early diagnosis, prognosis or 
monitoring a particular disease or may be used alongside 
conventional clinical tests as an alternative test for con-
firmation. Many methods have been described for quali-
tative and quantitative identification of CYP2E1. Earlier 
common qualitative methods for detection and identifi-
cation of CYP450 subtypes were gel electrophoresis [12] 
and immunoblotting [13, 14] which lacked sensitivity 
and specificity. In the past decade, the quantitative prot-
eomic approach gained popularity and many studies have 
attempted the application of trypic digest coupling with 
tandem LCMS analysis [15, 16] allowing absolute quanti-
tation of individual CYP450 isoforms. These approaches 
demonstrated higher specificity and sensitivity but to 
date (and according to our knowledge) no studies have 
described a validated targeted proteomic method for 
analyzing CYP450s in human peripheral blood. Since a 
few isoforms of CYP450s have been associated with dis-
eases, it will be worthwhile introducing a clinically appli-
cable method for quantitating CYP450s.
Although various studies have convincingly dictated 
the association of CYP2E1 [6–10] and reactive oxygen 
species (ROS) [17] in diabetes and its complications, 
there is lack of evidence on the changing profile of ROS 
and CYP2E1 levels with varying glycemic levels. Also, 
there is lack of evidence on the concurrency of ROS and 
CYP2E1 with gold standard clinical indices for glycemic 
control (HbA1c). The knowledge of the latter will further 
reaffirm that CYP2E1 is a candidate early biomolecule in 
diabetes progression. Therefore, the aims of this study 
were firstly, to optimize a targeted proteomic approach 
for quantitating CYP2E1 in peripheral blood; secondly, 
to validate its use alongside with clinical indices (HbA1c 
and fasting blood sugar) currently used in the clinical 
laboratory, and thirdly, to investigate the correlation of 
circulating CYP2E1 protein amounts with CYP2E1 gene 
expression and ROS.
Results and discussion
The representative peptides for CYP2E1 used in this 
study were YPEIEEK [P1 (amino acid position 318–325)] 
and GTVVVPTLYDNQEFPDPEK [P2 (amino acid posi-
tion: 386-408)]. P1 is suitable for universal quantifica-
tion of CYP2E1 in human due to absence of polymorphic 
regions. P2 was included as a confirmatory peptide to 
the former because it has been employed in other studies 
[15]. P2 may not be suitable as a representative peptide 
for universal application in CYP2E1 quantification due to 
natural amino acid variation between individuals at posi-
tion 389 [URL: http://www.uniprot.org]. An electrospray 
ionization source (ESI) was operated in the positive ioni-
zation mode for ion production. The most abundant and 
stable product ions from collision-induced dissociation 
of each analyte were selected as quantifier ions, while the 
second most abundant ions were selected as qualifier ions 
(Fig. 1a). An excellent separation of each analyte of inter-
est was achieved with total run time for each injection of 
only 5 min (Fig. 1b). The latter shows that the analytical 
method is highly selective for the analytes of interest.
Partial validation of the optimized chromatographic 
method showed P1 is a reliable representative peptide of 
CYP2E1 (Table 1) for the intended purpose of this ana-
lytical method. P2 showed unsatisfactory reproducibility 
and sensitivity in the ESI-LCMS/MS analysis. The normal 
reference limits for CYP2E1 protein in peripheral circula-
tion has not been documented to date. Therefore, to visu-
ally estimate the linear range, six independent calibration 
curves for each representative peptide were set-up. Each 
calibration curve consisted of 20 individual concentra-
tions ranging from 0 to 10,000 fg µL−1. The observed lin-
ear ranges for P1 and P2 were 5–100,000 fg µL−1 (Fig. 2a) 
and 100–1000 fg µL−1 (Fig. 2b), respectively. 
CYP2E1 is a non-abundant protein in human periph-
eral blood. Current study showed that CYP2E1 was not 
quantifiable in individuals with normal blood sugar lev-
els (euglycemia) but was quantifiable in some of the pre-
diabetic and most of diabetic subjects at varying amounts 
(Fig.  3a). The mean values for Pre-D and D groups 
were significantly different from the control group (C) 
(p < 0.001). No significant differences were seen between 
the means of Pre-D and D (p  =  0.870). CYP2E1 gene 
expression correspondingly showed up regulation when 
HbA1c was still within normal reference limits (Fig. 3b, 
c).
HbA1c is the gold standard point-of-care test for 
evaluating blood glucose levels and it is globally used by 
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Fig. 1 Representative chromatograms of analytes: YPEIEEK (P1), GTVVVPTLDSVLYDNQEFPDPEK (P2) and internal standards for YPEIEEK (P1-IS) and 
GTVVVPTLDSVLYDNQEFPDPEK (P2-IS). a 30 fg µL−1 mixture of P1, P2, P1-IS and P2-IS were prepared in pooled plasma from control subjects and 
injected into the Agilent 1100 UHPLC coupled to the Agilent 6410 ESI-LCMS/MS system for CYP2E1 analytical method development and opti-
mization. Stable and reproducible transition ions (m/z) were selected for MRM analysis: P1 = (precursor: 454.3; quantifier: 647.3; qualifier: 518.3); 
P1-IS = (precursor: 476.7; quantifier: 518.3; qualifier: 647.3); P2 = (precursor: 855.0; quantifier: 456.3; qualifier: 585.3); P2-IS = (precursor: 807.1; 
quantifier: 501.3; qualifier: 585.3). MRM multiple reaction monitoring; P1 peptide 1 (YPEIEEK); P1-IS internal standard for peptide 1; P2 peptide 2 
(GTVVVPTLDSVLYDNQEFPDPEK); P2-IS internal standard for peptide 2. b Representative chromatogram showing good resolution of each analyte 
of interest from a mixture containing 30 fg µL−1 of each analyte spiked pooled plasma from control subjects. The specific retention time for each 
analyte was P1: 1.041 min; IS-P1: 1.811 min; P2: 2.808 min and P2-IS: 4.118 min. Total run time for each sample was 5 min
Table 1 Summary of method validation data
The optimized analytical method for CYP2E1 quantification was validated by assessing the linear range, linearity, LLOQ, specificity, intra and inter-group accuracy and 
precision. IS-P1 internal standard for P1; IS-P2 internal standard for P2; NA not applicable. Coefficient of variation (CV, %) is presented as mean ± standard deviation. 
Coefficient of variation, means and standard deviations were calculated using the Sigma plot 11.2 software. Overall, the analytical method showed higher sensitivity 
and specificity for P1 (LLOQ = 5 fg µL−1; CV% = 4.0 ± 0.004) in comparison to P2 (LLOQ = 100 fg µL−1; CV% = 15.9 ± 0.42). Higher intra-day accuracy (L = 99.2 %; 
M = 99.8 %; H = 98.2 %) and precision (L: CV% = 3.64; M: CV% = 4.79; H: CV% = 10.93) were observed for quantification of P1 in comparison to P2 [(Accuracy) 
L = 41.0 %; M = 69.2 %; H = 70.6 % / (precision) L: CV% = 55.14; M: CV% = 5.32; H: CV% = 17.13]. Similarly, Inter-day accuracy for P1 (L = 91.75 %; M = 105.08%; 
H = 90.09 %) showed higher than 90 % accuracy for all levels of QC quantitated while P2 quantification showed slightly lower accuracy (L = 70.8 %; M = 82.6 %; 
H = 84.14 %) for all levels of QC in comparison to P1. Inter-day precision for quantification of P1 at all 3 QC levels showed CV% < 10 showing that the quantification 
method was highly precise for P1. P2 showed poor precision (L: CV% = 42.54 %; M: CV% = 12.62 and H: CV% = 20.13 %) for L and H QC levels. Overall, P1 showed 
higher reproducibility and reliability as representative peptide for CYP2E1 in the optimized targeted proteomic approach
Parameters YPEIEEK (P1) GTVVVPTLDSVLYDNQEFPDPEK 
(P2)
IS-P1 IS-P2
Linear range 5–100,000 fg/µl 100–12,500 fg/µl NA NA
Linearity r2 = 0.991 ± 0.007 r2 = 0.998 ± 0.001 NA NA
LLOQ 5 fg/µl 100 fg/µl NA NA
Specificity CV = 4.0 ± 0.04 % CV = 15.9 ± 0.42 % CV = 2.42 ± 0.05 % CV = 14.2 ± 0.57 %
Quality control: L M H L M H NA NA
Intra-day
 Accuracy, % 99.2 99.8 98.2 41.0 69.2 70.6 NA NA
 Precision, CV% 3.64 4.79 10.93 55.14 5.32 17.13 NA NA
Inter-day
 Accuracy, % 91.75 105.08 90.09 70.8 82.6 84.14 NA NA
 Precision, CV% 9.76 4.56 0.77 42.54 12.62 20.13 NA NA
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clinicians for diagnosis of diabetes as well as for evalu-
ating glycemic control alongside fasting blood glucose. 
When blood glucose exceeds homeostasis level it natu-
rally binds to haemoglobin to form glycosylated hemo-
globin (HbA1c). HbA1c values indicate average blood 
glucose levels for the past 2–3  months from the day 
HbA1c is tested on the patient [18]. The HbA1c test does 
not reflect on patients glycemic status beyond 3 months 
from the time of current test, unless HbA1c was tested 
once every 3 months repetitively. HbA1c levels continue 
to rise when blood sugar increases and decreases when 
patients consume oral antihyperglicemic drugs or when 
they undergo lifestyle modification as often prescribed 
by physicians. With regard to the latter, HbA1c does not 
represent cellular glucose metabolism processes during 
the hyperglycemia milieu which precedes the increase 
in blood glucose levels. Therefore, HbA1c values do not 
predict risks of diabetic complications.
Several studies commonly explained that within the 
hyperglycemic milieu ROS is grossly generated and 
promotes elevation of CYP2E1 protein levels [8–10]. 
CYP2E1 itself has oxidative properties [19] and along 
with glucose auto-oxidation is capable of generating 
more ROS which leads on to a positive turnover of ROS 
and CYP2E1; hence, enhancing a destructive environ-
ment at cellular level.
Measurement of ROS per se may not be suitable as 
an assessment of hyperglycemic related damage risk or 
severity of hyperglycemia. This is because the increase 
in ROS at any time may be transient due to the inter-
play of environmental factors, diet and various oxidants 
generated during normal intracellular metabolism. All 
these factors contribute to large inter-individual vari-
ations within each study group (Fig.  3d). The normal 
reference limit for ROS in human is ≤  310 FORT units 
(FORT  =  free oxygen radical test) [20]. Moreover, in 
the human body an efficient natural antioxidant defence 
mechanism exists which aims to maintain physiologi-
cal levels of ROS [21]. An imbalance of ROS homeosta-
sis takes place during the onset of diabetes bias towards 
ROS generation at cellular level [17]. The latter processes 
create a toxic-driven catastrophic environment which 
Fig. 2 Calibration curves for CYP2E1 specific tryptic peptides YPEIEEK (P1) and GTVVVPTLDSVLYDNQEFPDPEK (P2). a YPEIEEK calibration curve was 
constructed from serial dilutions of synthetic peptides and spiked in pooled plasma from control subjects containing 50 fg µL−1 of deuterated 
YPEIEEK as internal standard. Each data point is mean of triplicates and error bars represent standard deviation (SD) from the mean. The calibration 
curve showed linearity (R2 = 0.997) between concentrations 0–1000 fg µL−1. b GTVVVPTLDSVLYDNQEFPDPEK calibration curve was constructed 
from serial dilutions of synthetic peptides and spiked in pooled plasma from control subjects containing 50 fg µL−1 of deuterated YPEIEEK as inter-
nal standard. Each data point is mean of triplicates and error bars represents standard deviation (SD) from the mean. The calibration curve showed 
linearity (R2 = 0.989) between concentrations 0–1000 fg µL−1
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hypothetically triggers the up-regulation of CYP2E1 to 
play its physiological role to detoxify the environment. 
Consistent with diabetes being a systemic disease it is 
possible that this initial up-regulation of CYP2E1 gene 
occurs in peripheral lymphocytes and the CYP2E1 pro-
tein becomes quantifiable in peripheral lymphocytes. 
CYP2E1 itself has oxidative properties [1] therefore, sus-
tained increment in CYP2E1 will not be a favourable con-
dition and together with auto-oxidation of glucose the 
cellular environment becomes destroyed and can con-
tribute to multiple forms of pathogenesis.
Therefore, an undiagnosed diabetic patient who has 
abnormal HbA1c level at the first visit to a clinician may 
already be at risk for diabetic complications. According 
to clinical guidelines [22], HbA1C ≥ 6.5 % is equivalent 
to normal blood glucose level, but our data showed that 
CYP2E1 protein was quantifiable in some individuals 
even when HbA1C was  <  6.5  %. On average, CYP2E1 
Fig. 3 Correlation of CYP2E1 protein levels, CYP2E1 gene expression and ROS, with glycemic control. a A scatter plot generated using the SigmaPlot 
11.2 software, presenting measurable amounts of CYP2E1 protein in individual subjects (n = 166). Data from this scatter plot shows measurable 
amounts of CYP2E1 were seen even when HbA1c was 4.2 %. b CYP2E1 gene expression presented as a heat map generated using the GeneSpring 
12.6 software. The heat map shows averaged CYP2E1 gene expression of study subjects who were grouped according to their HbA1c percentage. 
The averaged CYP2E1 gene expression for the groups of subjects who had HbA1c [(< 5.0 %); n = 8] and [(5.1–6.0); n = 20] showed down regulation 
and groups for subjects with HbA1c percentage [(6.1–7.0); n = 19], [(7.1–8.0); n = 11], [(8.1–9.0); n = 20], [(9.1–10.0); n = 17],[(10.1–11.0); n = 9], 
[(11.1–12.0); n = 6], [(12.1–13.0); n = 6] showed up-regulation. The gradual change in hues of green from dark green for group (6.1–7.0) to the lightest 
green in group (12.1–13.0) shows the increments in up regulation intensities of CYP2E1 gene as the HbA1c percentage increases. c CYP2E1 gene 
expression presented as a heat map generated using the GeneSpring 12.6 software. The heat map shows CYP2E1 gene expression for individual 
subjects with various HbA1c percentages. The heat map shows that CYP2E1 gene is up regulated even when HbA1c was 5.4 %, which is well within 
the normal reference limit for HbA1c in clinical practice. d A bar chart representing average ROS levels in the groups of subjects who had HbA1c 
[(< 5.0 %); n = 8],[(5.1–6.0); n = 20], [(6.1–7.0); n = 19], [(7.1–8.0); n = 11], [(8.1–9.0); n = 20], [(9.1–10.0); n = 17], [(10.1–11.0); n = 9], [(11.1–12.0); 
n = 6] and [(12.1–13.0); n = 6]. Error bars represent standard deviations (SD) within each group. SD was calculated using the Sigma Plot 11.2 
software. Overall, the increment in ROS levels showed increment trends with increasing HbA1c percentage similar to CYP2E1 gene expression and 
protein amounts. This observation strongly supports the notion that the increase in ROS production during hyperglycemia induces up-regulation of 
CYP2E1 gene expression in peripheral lymphocytes and subsequently increases in CYP2E1 protein
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protein (Fig.  3a) as well as CYP2E1 gene expression 
(Fig.  3b, c) were higher in diabetic individuals who had 
higher glycemic levels (HbA1c). Findings from this study 
clearly suggest that the appearance of CYP2E1 protein 
in peripheral lymphocytes precedes glycosylation of 
haemoglobin. Data from this study also suggest that the 
conventional clinical criteria [22] for diagnosis of diabe-
tes based on HbA1c and fasting blood glucose alone may 
prevent early recognition of the risks of onset of diabetes 
and possibly its complications.
Quantification of CYP2E1 in diabetic patients gives a 
prediction of cumulative of oxidative damage and tox-
icity at cellular level due to hyperglycemia at the time 
the patient is tested for this marker. Since CYP2E1 was 
not detected in control subjects, the lowest quantifiable 
amounts during hyperglycemia should be regarded as a 
risk factor for diabetic complications because CYP2E1 
is catastrophic by nature and is capable of exacerbating 
cellular damage and can be potentiated by other extrinsic 
and genetic factors.
With complete validation of our optimized targeted 
proteomic approach method, quantification of CYP2E1 
in peripheral blood will be useful as an additional tool 
alongside current clinical indices for predicting risk of 
developing diabetes in patients with impaired glucose 
tolerance or impaired fasting glucose as well as for pre-
dicting risks for diabetic complications.
Our findings complement and strengthen previous dis-
cussions [17] on the role of ROS in diabetes progression. 
Data from this study clearly provide evidence that the 
amounts of ROS correlates incrementally with the sever-
ity of hyperglycemia indicated by increasing HbA1c lev-
els (Fig. 3d).
Conclusions
Consistent with the aims of our study, we evidently 
showed that the optimized targeted proteomic approach 
for quantifying CYP2E1 in peripheral blood is suitable 
for clinical application. “YPEIEEK” is unique to CYP2E1 
and does not carry any polymorphic regions. “YPEI-
EEK” showed high inter-day and intra-day accuracy and 
precision. Therefore, “YPEIEEK” is a suitable and reli-
able probe for quantification of CYP2E1 in the general 
population.
The increment of CYP2E1 protein was consistent with 
increment of HbA1c values (gold standard marker for 
glycemic control) in peripheral blood, but the former 
precedes abnormal HbA1c values. This observation evi-
dently suggests that CYP2E1 protein levels in peripheral 
blood is a potential candidate biomarker for risk of devel-
oping diabetes and probably its complications in pro-
longed hyperglycemia.
Data from this study showed in a cohesive manner, the 
amounts of circulating CYP2E1 protein amounts and 
gene expression in peripheral blood increases in parallel 
with ROS. This finding compliments and strengthens the 
notion that ROS is increasingly being generated during 
hyperglycemia and subsequently influences the up-regu-




Reagents were obtained from Sigma Chemicals Co. 
(St. Louis, MO) and Agilent Technologies (M) Pte. Ltd. 
unless otherwise stated. Recombinant human CYP2E1 
expressed in Escherichia coli was from Euro Science (M) 
Pte. Ltd. Synthetic peptides “YPEIEEK (P1)” and “GTV-
VVPTLYDNQEFPDPEK (P2)” were ordered from First 
BASE Laboratories (M) Pte. Ltd. LCMS analytical col-
umn was purchase from Agilent Technologies (M) Pte. 
Ltd.
Research design and study subjects
This study was a cross sectional study. Study population 
(n = 166) consisted of three groups: normal healthy indi-
viduals (Control; n = 45), pre-diabetes (Pre-D; n = 25), 
and diabetes (D; n  =  96). Our inclusion criteria were 
adult males and females aged 30–60  years and non-
smokers. Our exclusion criteria were pregnant women 
and individuals who just recovered from any form of ill-
ness or surgery. Study subjects were grouped based on 
fasting plasma glucose levels (FPG), HbA1c and oral glu-
cose tolerance test (OGTT) with reference to the Ameri-
can Diabetes Association (ADA) criteria for diagnosis of 
diabetes mellitus [23]. Control subjects (C) were indi-
viduals with fasting plasma glucose FPG < 5.6 mmol L−1 
and/or HbA1c <  6.5  % on the recruitment day. The 
OGTT test reveals individuals with impaired fasting glu-
cose (IFG) and impaired glucose tolerance (IGT). IFG is 
when plasma glucose level after an overnight fast (8 h) is 
≥  7.0 mmol L−1. IGT is when an individual has plasma 
glucose level ≥ 11.0 mmol L−1 2 h after consuming 75 g 
glucose. Individuals with IFG or IGT were assigned to 
the pre-diabetes group (Pre-D). Individuals who had 
2 h post prandial glucose ≥ 7.8 < 11.0 mmol L−1 or FPG 
≥ 6.7 < 7.0 mmol L−1 and/or HbA1c ≥ 5.7 < 6.5 % were 
assigned to the Pre-D group [23]. The diabetes group 
(D) consisted of individuals who had fasting plasma glu-
cose (FPG) ≥ 7.0 mmol L−1 and/or HbA1c ≥ 6.5 %, indi-
viduals with both IFG and IGT and individuals who are 
already on antihypertensive medication. All subjects were 
instructed not to consume any form of alcoholic bever-
ages or food for 7 days before phlebotomy. Subjects who 
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had any major health conditions within 5  months from 
the date of phlebotomy were excluded from participation. 
Characteristics of our study population are summarized 
in Table 2. Informed written consent was obtained from 
all subjects following human research ethics approval 
from the Ministry of Health Malaysia, Medical Research 
and Ethics Committee (NMRR: 12-501-11926). This 
study conforms to the Declaration of Helsinki.
Sample collection
All subjects were instructed to fast overnight and phle-
botomy was performed the following morning on each 
subject at our clinical research center (Monash University 
Medical Precinct). Approximately 8  µL of venous blood 
was collected into tubes containing EDTA anticoagulant. 
All phlebotomy sessions were between 8 a.m. till 11 a.m.
Selection of CYP2E1- specific tryptic peptides
CYP2E1 unique peptides were selected in silico [24, 25] 
using the Agilent Spectrum Mill peptide selector (Revision: 
3.3.084). Tryptic peptides which are portions of the mem-
brane spanning region of CYP2E1 and those containing 
natural variant amino acid sequences were identified and 
excluded using the UniProt software http://www.uniprot.
org/uniprot/PO5181. Subsequently, “YEPIEEK” and “GTV-
VVPTLDSVLYDNQEFPDPEK” were selected as suitable 
unique analytical target peptides to quantify CYP2E1.
Isolation of lymphocytes from venous blood
Peripheral blood lymphocytes were isolated using NycoPrep 
media (Axis-Shield, Oslo, Norway) according to an established 
method [26]. 8 ml whole blood from each subject was diluted 
with equal volume of 0.9 % NaCl in a 50 mL Falcon tube. 16 µL 
of diluted blood was then carefully layered on 8 ml NycoPrep 
media in another 50 µL Falcon tube. Falcon tubes were then 
capped to prevent the formation of aerosols. All tubes were 
then centrifuged at 800×g for 20 min at room temperature in 
a swing out rotor (Beckman, Allegra X-12, USA). After centrif-
ugation, the lymphocytes form a distinct band at the interface 
between the sample layer and the NycoPrep media. A pasture 
pipette was used to transfer the lymphocytes suspension into 
15 µL glass centrifuge tubes without removing the upper layer. 
Equal volume of phosphate buffered saline (PBS) was added 
into centrifuge tubes containing lymphocytes suspension, 
mixed by gently inverting the tubes until the lymphocytes 
were homogenously diluted. Next, all tubes were centrifuged 
at 400×g for 10 min at room temperature. Supernatants were 
discarded and lymphocytes were resuspended in PBS and 
centrifuged again at 400×g for 10 min at room temperature. 
Supernatants were discarded and 1  µL 0.1  M Tris–HCl pH 
7.4 was added into each tube, mixed gently to dislodge the 
lymphocytes and bring them to a homogenous suspension. 
All lymphocyte suspensions were then transferred into pre-
labeled 1.5  µL microfuge tubes and immediately stored at 
−80 °C until used for microsome preparation.
Preparation of lymphocyte microsomes
Microsomes were prepared according to established 
method [27] with slight modifications. Isolated lympho-
cytes stored at −80  °C were thawed gradually at room 
temperature, mixed gently by tapping at the bottom of 
the microfuge tubes and placed on ice. Lymphocytes 
were disrupted by sonication for 3 × 60 s on ice, followed 
by centrifugation at 10,000×g for 30 min at 4  °C (Beck-
man Coulter, Optima L-100 XP Ultracentrifuge). The 
supernatants were transferred into new microcentrifuge 
tubes, and centrifuged again at 100,000×g for 90 min at 
4 °C. From this step onwards, all supernatants were dis-
carded and the pelleted microsomes were resuspended 
in 100  mM sodium pyrophosphate buffer, pH 7.4, to 
inhibit the NADPH destructing pyrophosphatase activ-
ity of the microsome preparation. This was followed by 
another centrifugation at 100,000×g for 60 min at 4  °C. 
The washed microsomes were resuspended in 50  mM 
potassium phosphate buffer, pH 7.4, containing 0.1 mM 
EDTA, 0.1  mM dithiothreitol (DTT) and 20  % glycerol. 
Microsome suspensions were transferred into 1.5  µL 
microcentrifuge tubes and stored immediately at −80 °C 
until used for subsequent protocol.
Isolation of soluble CYP2E1
CYP2E1 is a membrane bound protein. To facilitate the 
analysis and quantification this protein is enriched and 
solubilized in order to maximize cleavage by trypsin during 
the in-solution digestion procedure. CYP2E1 tryptic pep-
tides were extracted similar to the procedure described by 
Liao et al. [28] with slight modifications to gain maximum 
Table 2 Characteristics of study population
Data are presented as mean ± SD
C control, Pre-D pre-diabetes, D diabetes, m male, f female, FBS fasting blood 
sugar
Variables Study groupings
C (n = 45) Pre-D (n = 25) D (n = 96)
Gender
 M 12 12 47
 F 33 13 49
Age (years) 42 ± 13 50 ± 11 54 ± 9
HbA1c (%) 4.4 ± 0.36 6.0 ± 0.39 8.7 ± 2.0
FBS (mmol L−1) 4.9 ± 0.48 6.0 ± 1.16 10.0 ± 4.68
CYP2E1 (ag µL−1)
0 ± 0 7.66 ± 16.39 10.0 ± 20.79
 p C vs Pre-D: p < 0.001 
C vs D: p < 0.001
Pre-D vs D: p = 0.905
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recovery. Briefly, lymphocyte microsomes were sonicated 
(Sonicator 3000, Misonix Inc., Farmingdale, NY) followed 
by centrifugation at 153,000×g for 30  min. Lymphocyte 
lysate protein concentration was determined using Pierce 
bicinchoninic acid (BCA) protein assay kit (Thermo Scien-
tific, IL, USA). Membrane bound proteins were solubilized 
by placing the resulting total membrane pellets in 0.2  % 
sodium cholate in 25  mM NH4HCO3 and vortexed con-
tinuously at 700 rpm for 60 min at room temperature. Sub-
sequently, the dissolved membrane proteins were heated 
at 90  °C for 5 min to denature the solubilized membrane 
proteins to make them amenable to cleavage by trypsin. 
All samples were allowed to cool at room temperature, 
then treated with trypsin (Sigma-Aldrich, catalog number: 
T0303) for 15 h at 37 °C. The substrate to trypsin ratio used 
was 50/1 (w/w). After hydrolysis, 50 fg µL−1 internal stand-
ard peptides (deuterated “GTVVVPTLDSVLYDNQEF-
PDPEK” and “YPEIEEK”) were added to each sample and 
centrifuged at 153,000×g for 30 min. Supernatants for each 
sample were transferred to clean tubes and equal volumes 
of acetonitrile were added. All samples were dried using a 
Vacufuge (Eppendorf AG, Hamburg, Germany).
Analysis and quantitation by MRM using UHPLC-ESI- LC–
MS/MS
Analytical parameters for quantitation of target pep-
tides were optimized on the Agilent 1100 UHPLC system 
(Agilent, Santa Clara, USA) which was connected to an 
ESI triple quadrupole mass spectrometer (Agilent 6410). 
The targeted unique peptides were separated on ZOR-
BAX Eclipse Plus C8 Rapid Resolution column (Agilent, 
RRHD; 2.1 × 50 mm; 1.8 µm particles) and eluted using a 
non-linear mobile phase schedule. The mobile phase con-
sisted of 0.1 % formic acid in water (solvent A) and 0.1 % 
formic acid in 90 % acetonitrile/water (solvent B).
Analytical method validation
Linearity and range
Synthetic peptides (YPEIEEK, and GTVVVPTLDSV-
LYDNQEFPDPEK) were serially diluted to obtain final 
concentrations of 1000, 800, 600, 400, 200, 100, 80, 60, 
40, 20, 10, 5 and 0 fg µL−1 in pooled plasma from nor-
mal volunteers containing 50  fg  µL−1 of each internal 
standard. Triplicates of each calibrator was injected 
into the LCMS/MS system to generate standard curves 
(n = 6).
Specificity
Synthetic peptides and internal standard peptides were 
prepared as a mixture containing 30 fg µL−1 of each pep-
tide in pooled plasma from normal volunteers. 1  µL of 
peptide mixture was injected into the LCMS/MS system. 
The injections were repeated 10 times in the same day. 
Specificity was evaluated by comparing the repeatability 
of retention times of each peptide [29, 30].
Accuracy
Three levels of quality control (QC) standards for each 
peptide (10, 30 and 60 fg µL−1) containing 50 fg µL−1 of 
each internal standard were prepared in pooled plasma 
from normal volunteers. Triplicates of each QC stand-
ards were injected and data were collected for 6 runs. 
The observed values for each QC were then predicted 
from a 7 points calibration curve (500, 250, 125, 50, 25, 




× 100. Percentage 
of accuracy was calculated by subtracting error (%) value 
from 100 %.
Precision
Precision was assessed by comparing the peak area ratios 
from 6 runs of QC standards (3 levels) for each peptide. 
Peak area ratio is calculated by dividing the area under 
the curve (AUC) for analyte peptide by AUC for internal 
standard peptide [29, 30]. Preparations of QC standards 
were similar to the QCs prepared for accuracy evalua-
tion. Mean (n  =  6) percentage coefficient of variation 
(CV) for each QC should be ≤15 % [29, 30].
Inter‑day precision
The procedure for precision and accuracy assessment 
was repeated for 6  days and the percentage of CV for 
6 days was calculated.
Intra‑day precision
The procedure for precision and accuracy assessment 
was repeated for 6 runs in a single day and the percentage 
of CV was calculated for observation.
Measurement of reactive oxygen species (ROS)
ROS was measured using a free oxygen radical monitor 
(FORM-OX; Callegari, Italy).
Measurement of HbA1c
Glycosylated hemoglobin (HbA1c) was measured using Afin-
ion AS100 analyzer (Axis-Shield, USA) according to manu-
facturer’s protocol. This instrument conforms to the National 
Glycohemoglobin Standardization Program (NGSP) and dia-
betes control and complications trial (DCCT) standards.
CYP2E1 gene expression
Total RNA was extracted from each sample using RNe-
asyPlus Micro Kit (Qiagen, Germany) according to man-
ufacturer’s protocol. Purity (A260/A280), RNA integrity 
number (RIN) and concentration of extracted total RNA 
were assessed using Agilent 2100 Bioanalyzer with RNA 
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6000 Nano Reagents (Agilent Technologies, Santa Clara, 
USA). Only samples with RIN 7.0 or higher were selected 
for the gene expression experiment. 100 ng of total RNA 
of each sample was processed and hybridized to Sure-
Print G3 Human Gene Expression Microarray platform 
(G4858A; Agilent Technologies, Santa Clara, USA) 
according to manufacturer’s protocol. Microarray slides 
were scanned using Agilent G4900DA Sure Scan Micro-
array Scanner (Agilent Technologies, Santa Clara, USA). 
After scanning the image data files were imported into 
the GeneSpring GX gene expression software, Version 
12.6 (Agilent Technologies, USA) for detailed analysis.
Statistical analysis
Significant difference in CYP2E1 protein levels between 
the studied groups (C, PD, D) were calculated using Sig-
maPlot 11.2 software. Since our study samples were not 
drawn from normally distributed populations with the 
same variances, we used the Mann–Whitney rank sum 
test. Statistical analysis was performed in a pair-wise 
manner (C versus PD; C versus D and PD versus D). Dif-
ferences between study groups were considered signifi-
cant at p  <  0.05. Intra-group variations for variables in 
subjects and study parameters were described as stand-
ard deviations (SD). SDs were also calculated using the 
SigmaPlot statistical software.
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